

# At-Home Health Diagnostics Market Forecasts to 2034 – Global Analysis By Product Type (Cassettes, Strips, Midstream, Digital Monitoring Devices, Instruments, Test Cups and Dip Cards), Test Type, Sample Type, Usage, Application, Distribution Channel, End User and By Geography

<https://marketpublishers.com/r/A878E0D0C43EEN.html>

Date: May 2026

Pages: 200

Price: US\$ 4,150.00 (Single User License)

ID: A878E0D0C43EEN

## Abstracts

According to Statistics MRC, the Global At-Home Health Diagnostics Market is accounted for \$31.4 billion in 2026 and is expected to reach \$72.8 billion by 2034 growing at a CAGR of 11.0% during the forecast period. At-home health diagnostics refers to consumer-operated medical testing devices and kits designed for use in non-clinical settings that enable individuals to self-collect biological samples, including blood, urine, saliva, and nasal swabs, and obtain diagnostic results without the direct involvement of healthcare professionals. These products include lateral flow immunoassay strips and cassettes, electrochemical biosensor monitoring devices, digital PCR-based molecular test platforms, smartphone-connected continuous monitoring sensors, and laboratory-analyzed mail-in sample collection kits that provide clinically actionable information for glucose management, infectious disease detection, pregnancy confirmation, cardiovascular risk assessment, and cancer screening across diverse consumer health applications.

Market Dynamics:

Driver:

Chronic disease self-management

The growing prevalence of diabetes, hypertension, and cardiovascular disease, combined with healthcare system capacity constraints and patient preference for home-based condition management, is driving strong consumer demand for at-home diagnostic devices enabling frequent self-monitoring without clinical visits. The global

diabetic population, exceeding 530 million individuals requiring regular glucose monitoring, represents the largest single demand driver for at-home diagnostic products, with continuous glucose monitor adoption creating premium recurring consumable revenue streams. Aging population demographics in developed economies are systematically expanding the consumer base for chronic disease home monitoring devices across Western markets.

Restraint:

Regulatory approval complexity

At-home diagnostic products require extensive clinical validation studies demonstrating equivalent accuracy to laboratory reference methods and regulatory approval under medical device frameworks in each target market, creating substantial development timelines and regulatory investment requirements that limit product innovation speed and new market entry. The FDA 510(k) and De Novo clearance pathways for novel at-home diagnostic devices require clinical equivalency data across diverse consumer population subgroups that generate multi-year development timelines for complex new test categories. Post-market surveillance requirements and adverse event reporting obligations create ongoing regulatory compliance costs that affect at-home diagnostics product profitability.

Opportunity:

Digital health platform integration

Integration of at-home diagnostic devices with consumer health applications, electronic health record systems, and telemedicine platforms is creating connected health ecosystems that transform point-of-care test results into actionable clinical insights supported by remote physician consultation, automated care management alerts, and population health analytics. Healthcare systems adopting remote patient monitoring programs for chronic disease management are deploying at-home diagnostic devices as core infrastructure within technology-enabled care pathways that generate structured utilization volumes. Digital health platform vendors are actively partnering with at-home diagnostic device manufacturers to create integrated testing and telehealth service bundles.

Threat:

Test accuracy consumer confidence

High-profile false positive and false negative performance incidents in at-home COVID-19 rapid antigen tests during the pandemic have elevated consumer and regulatory scrutiny of at-home diagnostic accuracy claims, creating confidence challenges that affect the adoption of rapid test formats across other diagnostic categories where self-test performance is perceived as inferior to laboratory confirmation. Consumer surveys consistently report accuracy concerns as the primary barrier to routine at-home diagnostic adoption beyond established glucose monitoring

applications, requiring substantial investment in consumer education and test performance transparency to expand self-testing behavior across new health screening categories.

#### Covid-19 Impact:

The pandemic created unprecedented global demand for at-home COVID-19 rapid antigen tests that permanently established consumer familiarity with self-testing behavior and drove massive investment in at-home diagnostics manufacturing capacity and distribution infrastructure. Emergency use authorizations for at-home molecular and antigen tests created regulatory precedents that are accelerating approval pathways for future at-home test categories. Post-pandemic, consumer self-testing adoption rates across infectious disease, chronic condition monitoring, and wellness screening categories remain substantially elevated compared to pre-pandemic baselines, validating the long-term behavioral shift toward home-based health diagnostics.

The instruments segment is expected to be the largest during the forecast period. The instruments segment is expected to account for the largest market share during the forecast period, due to the high capital value of digital monitoring devices and reader platforms that enable quantitative result interpretation and connectivity with consumer health management ecosystems. Continuous glucose monitors, digital blood pressure meters, and smartphone-connected pulse oximeters represent high-average-selling-price instrument platforms generating substantial revenue per unit combined with recurring consumable attachment that create sustainable business models for at-home diagnostics device companies. Healthcare system remote patient monitoring program deployments are driving large-volume instrument procurement through clinical channels.

The glucose monitoring segment is expected to have the highest CAGR during the forecast period.

Over the forecast period, the glucose monitoring segment is predicted to witness the highest growth rate, driven by rapid consumer adoption of continuous glucose monitor technology by the vastly larger pre-diabetic and metabolic health-conscious consumer population beyond the established insulin-dependent diabetic patient base. Consumer wellness applications of CGM technology for dietary optimization, exercise performance, and metabolic health tracking are expanding the addressable population for glucose monitoring beyond traditional clinical indications. Major CGM manufacturers including Abbott, Dexcom, and Medtronic are launching over-the-counter CGM products targeting mainstream consumer wellness markets at accessible consumer price points.

#### Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share, due to the highest per-capita spending on consumer health technology, the largest established base of chronically managed patients requiring regular home

monitoring, and the most developed direct-to-consumer diagnostics retail and telehealth distribution infrastructure. The United States hosts the world's largest at-home diagnostics market with established consumer behavior for glucose monitoring and pregnancy testing and rapidly growing adoption of connected health monitoring devices. Major diagnostics companies including Abbott, Roche, and Becton Dickinson maintain dominant market positions.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR, due to the world's largest diabetic population concentrated in China and India driving massive demand for glucose monitoring devices, combined with rapidly expanding consumer healthcare spending across middle-class populations in China, South Korea, and Southeast Asian markets. China's national chronic disease management programs promoting home monitoring and digital health adoption are driving systematic at-home diagnostics infrastructure deployment. India's large underserved rural population accessing preventive healthcare through at-home testing represents a significant untapped demand opportunity.

Key players in the market

Some of the key players in At-Home Health Diagnostics Market include Abbott Laboratories, Roche Holding AG, Siemens Healthineers AG, Becton, Dickinson and Company, Danaher Corporation, Thermo Fisher Scientific Inc., QuidelOrtho Corporation, OraSure Technologies Inc., Dexcom Inc., Bio-Rad Laboratories Inc., Abbott Diabetes Care Inc., ACON Laboratories Inc., iHealth Labs Inc., Lucent Diagnostics LLC, Cue Health Inc., Everly Health Inc., LetsGetChecked, and MyLab Box Inc..

Key Developments:

In March 2026, Everlywell Inc. announced a strategic partnership with a national telehealth provider creating integrated at-home testing and physician consultation services for comprehensive preventive health screening programs.

In February 2026, Roche Holding AG expanded at-home diagnostics portfolio with a connected multi-biomarker monitoring platform integrating glucose, ketone, and lactate measurement for chronic metabolic condition management.

In December 2025, Dexcom Inc. received FDA clearance for an over-the-counter continuous glucose monitoring system enabling unsupervised consumer self-application for non-prescription metabolic health monitoring applications.

Product Types Covered:

Cassettes

Strips

Midstream

Digital Monitoring Devices

Instruments

Test Cups

Dip Cards

#### Test Types Covered:

Glucose Monitoring

Infectious Disease Testing

Pregnancy & Fertility Testing

Cholesterol & Lipid Profile Testing

Drug of Abuse Testing

Urinary Tract Infection Testing

Fecal Occult Blood Testing

Genetic Testing

Allergy Testing

#### Sample Types Covered:

Blood

Urine

Saliva

Nasal Swab

Stool

#### Usages Covered:

Disposable

Reusable

#### Applications Covered:

Chronic Disease Management

Preventive Healthcare

Infectious Disease Screening

Wellness Monitoring

#### Distribution Channels Covered:

Retail Pharmacies

Drug Stores

Supermarkets & Hypermarkets

Online Pharmacies

Direct-to-Consumer

#### End Users Covered:

Individuals

Clinics

Other End Users

## Regions Covered:

### North America

United States

Canada

Mexico

### Europe

United Kingdom

Germany

France

Italy

Spain

Netherlands

Belgium

Sweden

Switzerland

Poland

Rest of Europe

Asia Pacific

China

Japan

India

South Korea

Australia

Indonesia

Thailand

Malaysia

Singapore

Vietnam

Rest of Asia Pacific

South America

Brazil

Argentina

Colombia

Chile

Peru

Rest of South America

## Rest of the World (RoW)

### Middle East

Saudi Arabia

United Arab Emirates

Qatar

Israel

Rest of Middle East

### Africa

South Africa

Egypt

Morocco

Rest of Africa

## What our report offers:

Market share assessments for the regional and country-level segments

Strategic recommendations for the new entrants

Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034

Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)

Strategic recommendations in key business segments based on the market

estimations

Competitive landscaping mapping the key common trends

Company profiling with detailed strategies, financials, and recent developments

Supply chain trends mapping the latest technological advancements

#### Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

##### Company Profiling

Comprehensive profiling of additional market players (up to 3)

SWOT Analysis of key players (up to 3)

##### Regional Segmentation

Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)

##### Competitive Benchmarking

Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

## Contents

### **1 EXECUTIVE SUMMARY**

- 1.1 Market Snapshot and Key Highlights
- 1.2 Growth Drivers, Challenges, and Opportunities
- 1.3 Competitive Landscape Overview
- 1.4 Strategic Insights and Recommendations

### **2 RESEARCH FRAMEWORK**

- 2.1 Study Objectives and Scope
- 2.2 Stakeholder Analysis
- 2.3 Research Assumptions and Limitations
- 2.4 Research Methodology
  - 2.4.1 Data Collection (Primary and Secondary)
  - 2.4.2 Data Modeling and Estimation Techniques
  - 2.4.3 Data Validation and Triangulation
  - 2.4.4 Analytical and Forecasting Approach

### **3 MARKET DYNAMICS AND TREND ANALYSIS**

- 3.1 Market Definition and Structure
- 3.2 Key Market Drivers
- 3.3 Market Restraints and Challenges
- 3.4 Growth Opportunities and Investment Hotspots
- 3.5 Industry Threats and Risk Assessment
- 3.6 Technology and Innovation Landscape
- 3.7 Emerging and High-Growth Markets
- 3.8 Regulatory and Policy Environment
- 3.9 Impact of COVID-19 and Recovery Outlook

### **4 COMPETITIVE AND STRATEGIC ASSESSMENT**

- 4.1 Porter's Five Forces Analysis
  - 4.1.1 Supplier Bargaining Power
  - 4.1.2 Buyer Bargaining Power
  - 4.1.3 Threat of Substitutes
  - 4.1.4 Threat of New Entrants

- 4.1.5 Competitive Rivalry
- 4.2 Market Share Analysis of Key Players
- 4.3 Product Benchmarking and Performance Comparison

## **5 GLOBAL AT-HOME HEALTH DIAGNOSTICS MARKET, BY PRODUCT TYPE**

- 5.1 Cassettes
- 5.2 Strips
- 5.3 Midstream
- 5.4 Digital Monitoring Devices
- 5.5 Instruments
- 5.6 Test Cups
- 5.7 Dip Cards

## **6 GLOBAL AT-HOME HEALTH DIAGNOSTICS MARKET, BY TEST TYPE**

- 6.1 Glucose Monitoring
  - 6.1.1 Blood Glucose Monitors
  - 6.1.2 Continuous Glucose Monitors
- 6.2 Infectious Disease Testing
  - 6.2.1 COVID-19 Test Kits
  - 6.2.2 HIV Test Kits
  - 6.2.3 Influenza Test Kits
  - 6.2.4 Sexually Transmitted Infection Tests
- 6.3 Pregnancy & Fertility Testing
  - 6.3.1 Pregnancy Test Kits
  - 6.3.2 Ovulation Predictor Kits
- 6.4 Cholesterol & Lipid Profile Testing
- 6.5 Drug of Abuse Testing
- 6.6 Urinary Tract Infection Testing
- 6.7 Fecal Occult Blood Testing
- 6.8 Genetic Testing
- 6.9 Allergy Testing

## **7 GLOBAL AT-HOME HEALTH DIAGNOSTICS MARKET, BY SAMPLE TYPE**

- 7.1 Blood
- 7.2 Urine
- 7.3 Saliva

7.4 Nasal Swab

7.5 Stool

## **8 GLOBAL AT-HOME HEALTH DIAGNOSTICS MARKET, BY USAGE**

8.1 Disposable

8.2 Reusable

## **9 GLOBAL AT-HOME HEALTH DIAGNOSTICS MARKET, BY APPLICATION**

9.1 Chronic Disease Management

9.2 Preventive Healthcare

9.3 Infectious Disease Screening

9.4 Wellness Monitoring

## **10 GLOBAL AT-HOME HEALTH DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL**

10.1 Retail Pharmacies

10.2 Drug Stores

10.3 Supermarkets & Hypermarkets

10.4 Online Pharmacies

10.5 Direct-to-Consumer

## **11 GLOBAL AT-HOME HEALTH DIAGNOSTICS MARKET, BY END USER**

11.1 Individuals

11.2 Clinics

11.3 Other End Users

## **12 GLOBAL AT-HOME HEALTH DIAGNOSTICS MARKET, BY GEOGRAPHY**

12.1 North America

12.1.1 United States

12.1.2 Canada

12.1.3 Mexico

12.2 Europe

12.2.1 United Kingdom

12.2.2 Germany

- 12.2.3 France
- 12.2.4 Italy
- 12.2.5 Spain
- 12.2.6 Netherlands
- 12.2.7 Belgium
- 12.2.8 Sweden
- 12.2.9 Switzerland
- 12.2.10 Poland
- 12.2.11 Rest of Europe
- 12.3 Asia Pacific
  - 12.3.1 China
  - 12.3.2 Japan
  - 12.3.3 India
  - 12.3.4 South Korea
  - 12.3.5 Australia
  - 12.3.6 Indonesia
  - 12.3.7 Thailand
  - 12.3.8 Malaysia
  - 12.3.9 Singapore
  - 12.3.10 Vietnam
  - 12.3.11 Rest of Asia Pacific
- 12.4 South America
  - 12.4.1 Brazil
  - 12.4.2 Argentina
  - 12.4.3 Colombia
  - 12.4.4 Chile
  - 12.4.5 Peru
  - 12.4.6 Rest of South America
- 12.5 Rest of the World (RoW)
  - 12.5.1 Middle East
    - 12.5.1.1 Saudi Arabia
    - 12.5.1.2 United Arab Emirates
    - 12.5.1.3 Qatar
    - 12.5.1.4 Israel
    - 12.5.1.5 Rest of Middle East
  - 12.5.2 Africa
    - 12.5.2.1 South Africa
    - 12.5.2.2 Egypt
    - 12.5.2.3 Morocco

#### 12.5.2.4 Rest of Africa

### **13 STRATEGIC MARKET INTELLIGENCE**

13.1 Industry Value Network and Supply Chain Assessment

13.2 White-Space and Opportunity Mapping

13.3 Product Evolution and Market Life Cycle Analysis

13.4 Channel, Distributor, and Go-to-Market Assessment

### **14 INDUSTRY DEVELOPMENTS AND STRATEGIC INITIATIVES**

14.1 Mergers and Acquisitions

14.2 Partnerships, Alliances, and Joint Ventures

14.3 New Product Launches and Certifications

14.4 Capacity Expansion and Investments

14.5 Other Strategic Initiatives

### **15 COMPANY PROFILES**

15.1 Abbott Laboratories

15.2 Roche Holding AG

15.3 Siemens Healthineers AG

15.4 Becton, Dickinson and Company

15.5 Danaher Corporation

15.6 Thermo Fisher Scientific Inc.

15.7 QuidelOrtho Corporation

15.8 OraSure Technologies Inc.

15.9 Dexcom Inc.

15.10 Bio-Rad Laboratories Inc.

15.11 Abbott Diabetes Care Inc.

15.12 ACON Laboratories Inc.

15.13 iHealth Labs Inc.

15.14 Lucent Diagnostics LLC

15.15 Cue Health Inc.

15.16 Everly Health Inc.

15.17 LetsGetChecked

15.18 MyLab Box Inc.

## List Of Tables

### LIST OF TABLES

Table 1 Global At-Home Health Diagnostics Market Outlook, By Region (2023-2034) (\$MN)

Table 2 Global At-Home Health Diagnostics Market Outlook, By Product Type (2023-2034) (\$MN)

Table 3 Global At-Home Health Diagnostics Market Outlook, By Cassettes (2023-2034) (\$MN)

Table 4 Global At-Home Health Diagnostics Market Outlook, By Strips (2023-2034) (\$MN)

Table 5 Global At-Home Health Diagnostics Market Outlook, By Midstream (2023-2034) (\$MN)

Table 6 Global At-Home Health Diagnostics Market Outlook, By Digital Monitoring Devices (2023-2034) (\$MN)

Table 7 Global At-Home Health Diagnostics Market Outlook, By Instruments (2023-2034) (\$MN)

Table 8 Global At-Home Health Diagnostics Market Outlook, By Test Cups (2023-2034) (\$MN)

Table 9 Global At-Home Health Diagnostics Market Outlook, By Dip Cards (2023-2034) (\$MN)

Table 10 Global At-Home Health Diagnostics Market Outlook, By Test Type (2023-2034) (\$MN)

Table 11 Global At-Home Health Diagnostics Market Outlook, By Glucose Monitoring (2023-2034) (\$MN)

Table 12 Global At-Home Health Diagnostics Market Outlook, By Blood Glucose Monitors (2023-2034) (\$MN)

Table 13 Global At-Home Health Diagnostics Market Outlook, By Continuous Glucose Monitors (2023-2034) (\$MN)

Table 14 Global At-Home Health Diagnostics Market Outlook, By Infectious Disease Testing (2023-2034) (\$MN)

Table 15 Global At-Home Health Diagnostics Market Outlook, By COVID-19 Test Kits (2023-2034) (\$MN)

Table 16 Global At-Home Health Diagnostics Market Outlook, By HIV Test Kits (2023-2034) (\$MN)

Table 17 Global At-Home Health Diagnostics Market Outlook, By Influenza Test Kits (2023-2034) (\$MN)

Table 18 Global At-Home Health Diagnostics Market Outlook, By Sexually Transmitted

Infection Tests (2023-2034) (\$MN)

Table 19 Global At-Home Health Diagnostics Market Outlook, By Pregnancy & Fertility Testing (2023-2034) (\$MN)

Table 20 Global At-Home Health Diagnostics Market Outlook, By Pregnancy Test Kits (2023-2034) (\$MN)

Table 21 Global At-Home Health Diagnostics Market Outlook, By Ovulation Predictor Kits (2023-2034) (\$MN)

Table 22 Global At-Home Health Diagnostics Market Outlook, By Cholesterol & Lipid Profile Testing (2023-2034) (\$MN)

Table 23 Global At-Home Health Diagnostics Market Outlook, By Drug of Abuse Testing (2023-2034) (\$MN)

Table 24 Global At-Home Health Diagnostics Market Outlook, By Urinary Tract Infection Testing (2023-2034) (\$MN)

Table 25 Global At-Home Health Diagnostics Market Outlook, By Fecal Occult Blood Testing (2023-2034) (\$MN)

Table 26 Global At-Home Health Diagnostics Market Outlook, By Genetic Testing (2023-2034) (\$MN)

Table 27 Global At-Home Health Diagnostics Market Outlook, By Allergy Testing (2023-2034) (\$MN)

Table 28 Global At-Home Health Diagnostics Market Outlook, By Sample Type (2023-2034) (\$MN)

Table 29 Global At-Home Health Diagnostics Market Outlook, By Blood (2023-2034) (\$MN)

Table 30 Global At-Home Health Diagnostics Market Outlook, By Urine (2023-2034) (\$MN)

Table 31 Global At-Home Health Diagnostics Market Outlook, By Saliva (2023-2034) (\$MN)

Table 32 Global At-Home Health Diagnostics Market Outlook, By Nasal Swab (2023-2034) (\$MN)

Table 33 Global At-Home Health Diagnostics Market Outlook, By Stool (2023-2034) (\$MN)

Table 34 Global At-Home Health Diagnostics Market Outlook, By Usage (2023-2034) (\$MN)

Table 35 Global At-Home Health Diagnostics Market Outlook, By Disposable (2023-2034) (\$MN)

Table 36 Global At-Home Health Diagnostics Market Outlook, By Reusable (2023-2034) (\$MN)

Table 37 Global At-Home Health Diagnostics Market Outlook, By Application (2023-2034) (\$MN)

Table 38 Global At-Home Health Diagnostics Market Outlook, By Chronic Disease Management (2023-2034) (\$MN)

Table 39 Global At-Home Health Diagnostics Market Outlook, By Preventive Healthcare (2023-2034) (\$MN)

Table 40 Global At-Home Health Diagnostics Market Outlook, By Infectious Disease Screening (2023-2034) (\$MN)

Table 41 Global At-Home Health Diagnostics Market Outlook, By Wellness Monitoring (2023-2034) (\$MN)

Table 42 Global At-Home Health Diagnostics Market Outlook, By Distribution Channel (2023-2034) (\$MN)

Table 43 Global At-Home Health Diagnostics Market Outlook, By Retail Pharmacies (2023-2034) (\$MN)

Table 44 Global At-Home Health Diagnostics Market Outlook, By Drug Stores (2023-2034) (\$MN)

Table 45 Global At-Home Health Diagnostics Market Outlook, By Supermarkets & Hypermarkets (2023-2034) (\$MN)

Table 46 Global At-Home Health Diagnostics Market Outlook, By Online Pharmacies (2023-2034) (\$MN)

Table 47 Global At-Home Health Diagnostics Market Outlook, By Direct-to-Consumer (2023-2034) (\$MN)

Table 48 Global At-Home Health Diagnostics Market Outlook, By End User (2023-2034) (\$MN)

Table 49 Global At-Home Health Diagnostics Market Outlook, By Individuals (2023-2034) (\$MN)

Table 50 Global At-Home Health Diagnostics Market Outlook, By Clinics (2023-2034) (\$MN)

Table 51 Global At-Home Health Diagnostics Market Outlook, By Other End Users (2023-2034) (\$MN)

Note: Tables for North America, Europe, APAC, South America, and Rest of the World (RoW) Regions are also represented in the same manner as above.

## I would like to order

Product name: At-Home Health Diagnostics Market Forecasts to 2034 – Global Analysis By Product Type (Cassettes, Strips, Midstream, Digital Monitoring Devices, Instruments, Test Cups and Dip Cards), Test Type, Sample Type, Usage, Application, Distribution Channel, End User and By Geography

Product link: <https://marketpublishers.com/r/A878E0D0C43EEN.html>

Price: US\$ 4,150.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/A878E0D0C43EEN.html>